Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Editorial

Targeted Drug Delivery and Theragnostics

Author(s): Kalevi Kairemo

Volume 26, Issue 31, 2020

Page: [3781 - 3782] Pages: 2

DOI: 10.2174/138161282631200810124049

[1]
Assadi M, Jokar N, Ghasemi M, et al. Precision Medicine Approach in Prostate Cancer. Curr Pharm Des 2020; 26(31): 3783-98.
[2]
Turner JH. Real-World Evidence of Clinical Outcomes in Precision Radionuclide Oncology: The NIGHTCAP Study of 177Lu-PSMA in Metastatic Prostate Cancer. Curr Pharm Des 2020; 26(31): 3799-803.
[3]
Jokar N, Assadi M, Yordanova A, Ahmadzadehfar H. Bench-to-Bedside Theranostics in Nuclear Medicine. Curr Pharm Des 2020; 26(31): 3804-11.
[4]
Slonimsky E, Tulchinsky M. Radiotheragnostics Paradigm for Radioactive Iodine (Iodide) Management of Differentiated Thyroid Cancer. Curr Pharm Des 2020; 26(31): 3812-27.
[5]
Peñate Medina T, Kraas E, Luo K, et al. Utilizing ICG Spectroscopical Properties for Real-Time Nanoparticle Release Quantification In vitro and In vivo in Imaging Setups. Curr Pharm Des 2020; 26(31): 3828-33.
[6]
Kågedal Å, Margolin G, Held C, et al. A Novel Sentinel Lymph Node Approach in Oral Squamous Cell Carcinoma. Curr Pharm Des 2020; 26(31): 3834-9.
[7]
Peñate Medina T, Damoah C, Benezra M, et al. Alpha-MSH Targeted Liposomal Nanoparticle for Imaging in Inflammatory Bowel Disease (IBD). Curr Pharm Design 2020; 26(31): 3840-46.

© 2024 Bentham Science Publishers | Privacy Policy